MENU
+Compare
CASI
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$2.45
Change
-$0.01 (-0.41%)
Capitalization
37.96M

CASI CASI Pharmaceuticals Forecast, Technical & Fundamental Analysis

a developer of pharmaceutical drugs for treating cancer and inflammatory diseases

Industry Biotechnology
CASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CASI with price predictions
Feb 18, 2025

CASI in upward trend: price may ascend as a result of having broken its lower Bollinger Band on January 29, 2025

CASI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 42 cases where CASI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where CASI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on February 12, 2025. You may want to consider a long position or call options on CASI as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CASI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CASI entered a downward trend on February 07, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.741) is normal, around the industry mean (12.604). P/E Ratio (0.000) is within average values for comparable stocks, (85.387). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.581). CASI has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (1.544) is also within normal values, averaging (252.111).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CASI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CASI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical drugs for treating cancer and inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
No. 81, Jianguo Road
Phone
+86 01065618789
Employees
243
Web
https://www.casipharmaceuticals.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL245.55-0.28
-0.11%
Apple
BTC.X96258.000000-319.757800
-0.33%
Bitcoin cryptocurrency
SPY599.94-10.44
-1.71%
SPDR® S&P 500® ETF Trust
GME26.42-0.62
-2.29%
GameStop Corp
TSLA337.80-16.60
-4.68%
Tesla

CASI and Stocks

Correlation & Price change

A.I.dvisor tells us that CASI and ATRA have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CASI and ATRA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CASI
1D Price
Change %
CASI100%
+1.00%
ATRA - CASI
32%
Poorly correlated
-5.94%
KALA - CASI
30%
Poorly correlated
-13.84%
RIGL - CASI
30%
Poorly correlated
-3.85%
VICP - CASI
29%
Poorly correlated
N/A
ADCT - CASI
26%
Poorly correlated
+5.00%
More